Viridian Therapeutics, Inc.\DE - 8-K Filing

Viridian Therapeutics reports positive Phase 1 clinical trial results for VRDN-008 showing 74% peak IgG reduction and extended half-life. (Items: 7.01 Regulation FD Disclosure On November 9, 2026, Viridian Therapeutics, Inc, 8.01 Other Events On November 9, 2026, the Company announced positive results of a phase 1 clinical trial in healthy volunteers of VRDN-008, a hal, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 12:33 UTC

Tickers: $VRDN

Read the full article at SEC EDGAR

More Regulatory news

XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC